[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=dd47dc1f505a1d0fd6016ccfd6720a3f53762a417a0b69369511a2fdc0d6c5af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770303616,
      "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 138366223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=dd47dc1f505a1d0fd6016ccfd6720a3f53762a417a0b69369511a2fdc0d6c5af"
    }
  },
  {
    "ts": null,
    "headline": "WuXi Biologics Alliances Deepen Autoimmune And Next Gen Antibody Exposure",
    "summary": "WuXi Biologics (Cayman) has entered three new alliances with Vertex Pharmaceuticals, Sinorda Biomedicine, and HanchorBio. The partnerships focus on antibody therapeutics for autoimmune diseases and advanced bi and multi functional fusion programs. The collaborations expand WuXi Biologics' role in global biologics research and manufacturing and its work in T cell engager therapies. For investors watching SEHK:2269, these agreements arrive with the stock at HK$37.52 and a 1 year return of...",
    "url": "https://finnhub.io/api/news?id=1be88a1dc297e4eac3dcdb36f168a795823e05de6e71acdacf9465eb6acb0625",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296974,
      "headline": "WuXi Biologics Alliances Deepen Autoimmune And Next Gen Antibody Exposure",
      "id": 138363623,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "WuXi Biologics (Cayman) has entered three new alliances with Vertex Pharmaceuticals, Sinorda Biomedicine, and HanchorBio. The partnerships focus on antibody therapeutics for autoimmune diseases and advanced bi and multi functional fusion programs. The collaborations expand WuXi Biologics' role in global biologics research and manufacturing and its work in T cell engager therapies. For investors watching SEHK:2269, these agreements arrive with the stock at HK$37.52 and a 1 year return of...",
      "url": "https://finnhub.io/api/news?id=1be88a1dc297e4eac3dcdb36f168a795823e05de6e71acdacf9465eb6acb0625"
    }
  },
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback",
    "summary": "Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you are not alone in asking that question. The stock is around US$470.52 after a 1.5% decline over the last 7 days, a 4.8% gain over 30 days, a 4.1% gain year to date, and a 3.7% decline over the past year, on top of a 60.4% return over 3 years and 121.4% over 5 years. Recent news coverage has focused on Vertex Pharmaceuticals as a key player in the large cap biotech...",
    "url": "https://finnhub.io/api/news?id=949e14c5aeee4272ee7c7c5093386fbabbe529edf48393e50b15c5835890e432",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770279054,
      "headline": "Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback",
      "id": 138362138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you are not alone in asking that question. The stock is around US$470.52 after a 1.5% decline over the last 7 days, a 4.8% gain over 30 days, a 4.1% gain year to date, and a 3.7% decline over the past year, on top of a 60.4% return over 3 years and 121.4% over 5 years. Recent news coverage has focused on Vertex Pharmaceuticals as a key player in the large cap biotech...",
      "url": "https://finnhub.io/api/news?id=949e14c5aeee4272ee7c7c5093386fbabbe529edf48393e50b15c5835890e432"
    }
  },
  {
    "ts": null,
    "headline": "3 Market-Beating Stocks Worth Investigating",
    "summary": "Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.",
    "url": "https://finnhub.io/api/news?id=bb172078de74cfcaf4dbe70fc0693ff6e6c4a520c4bced17b186acd55cc834cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770266113,
      "headline": "3 Market-Beating Stocks Worth Investigating",
      "id": 138362744,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.",
      "url": "https://finnhub.io/api/news?id=bb172078de74cfcaf4dbe70fc0693ff6e6c4a520c4bced17b186acd55cc834cd"
    }
  }
]